SK10082003A3 - Väzbové molekuly a farmaceutická kompozícia, ktorá ich obsahuje - Google Patents

Väzbové molekuly a farmaceutická kompozícia, ktorá ich obsahuje Download PDF

Info

Publication number
SK10082003A3
SK10082003A3 SK1008-2003A SK10082003A SK10082003A3 SK 10082003 A3 SK10082003 A3 SK 10082003A3 SK 10082003 A SK10082003 A SK 10082003A SK 10082003 A3 SK10082003 A3 SK 10082003A3
Authority
SK
Slovakia
Prior art keywords
seq
polypeptide
amino acid
binding molecule
acid sequence
Prior art date
Application number
SK1008-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Gregorio Aversa
Frank Kolbinger
Herrera Jos� M. Carballido
Andr�S Asz�Di
Jos� W. Saldanha
Bruce M. Hall
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK10082003A3 publication Critical patent/SK10082003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1008-2003A 2001-02-12 2002-02-11 Väzbové molekuly a farmaceutická kompozícia, ktorá ich obsahuje SK10082003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0103389.3A GB0103389D0 (en) 2001-02-12 2001-02-12 Organic compounds
PCT/EP2002/001420 WO2002072832A2 (en) 2001-02-12 2002-02-11 Therapeutic binding molecules

Publications (1)

Publication Number Publication Date
SK10082003A3 true SK10082003A3 (sk) 2004-03-02

Family

ID=9908539

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1008-2003A SK10082003A3 (sk) 2001-02-12 2002-02-11 Väzbové molekuly a farmaceutická kompozícia, ktorá ich obsahuje

Country Status (25)

Country Link
US (1) US20040096901A1 (de)
EP (1) EP1421191B1 (de)
JP (2) JP2004533816A (de)
KR (1) KR100752029B1 (de)
CN (1) CN100529074C (de)
AR (1) AR035539A1 (de)
AT (1) ATE526409T1 (de)
BR (1) BR0207151A (de)
CA (1) CA2437963A1 (de)
CZ (1) CZ20032129A3 (de)
EC (1) ECSP034714A (de)
ES (1) ES2374554T3 (de)
GB (1) GB0103389D0 (de)
HU (1) HUP0401560A3 (de)
IL (1) IL157136A0 (de)
MX (1) MXPA03007197A (de)
NO (1) NO20033549L (de)
NZ (1) NZ548865A (de)
PE (1) PE20020871A1 (de)
PL (1) PL369516A1 (de)
RU (2) RU2405790C2 (de)
SK (1) SK10082003A3 (de)
TW (1) TWI332524B (de)
WO (1) WO2002072832A2 (de)
ZA (1) ZA200305911B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
US7618788B2 (en) * 2002-05-10 2009-11-17 Millipore Corporation Proteome epitope tags and methods of use thereof in protein modification analysis
CA2537217A1 (en) * 2003-09-18 2005-03-24 Novartis Ag Therapeutic binding molecules
EP1851308B1 (de) 2005-02-02 2013-08-21 NewSouth Innovations Pty Limited Gegen ein spezifisches antigen aktivierte cd4+ cd25+ t-zellen
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US7855057B2 (en) * 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
AU2008258646A1 (en) * 2007-06-05 2008-12-11 Fondazione Centro San Raffaele Del Monte Tabor Induction of tolerogenic phenotype in mature dendritic cells
CN102686733A (zh) * 2009-10-16 2012-09-19 陶氏益农公司 树枝状聚合物纳米技术用于将生物分子投递入植物细胞中的用途
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2502631A1 (de) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunsuppressor und seine Verwendung
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3026060A1 (de) * 2014-11-26 2016-06-01 Miltenyi Biotec GmbH CD45R0-spezifischer, humanisierter Antikörper oder Fragment davon
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US20230374148A1 (en) 2020-10-15 2023-11-23 UCB Biopharma SRL Binding molecules that multimerise cd45

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
ES2191702T3 (es) * 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
JPH09191886A (ja) * 1996-01-19 1997-07-29 Asahi Breweries Ltd ヒト高親和性ＩｇＥ受容体に対するヒト型化抗体、半キメラ抗体およびキメラ抗体

Also Published As

Publication number Publication date
AR035539A1 (es) 2004-06-02
WO2002072832A3 (en) 2004-03-25
RU2008100239A (ru) 2009-07-20
CN1551919A (zh) 2004-12-01
RU2405790C2 (ru) 2010-12-10
GB0103389D0 (en) 2001-03-28
EP1421191B1 (de) 2011-09-28
KR100752029B1 (ko) 2007-08-28
ES2374554T3 (es) 2012-02-17
CN100529074C (zh) 2009-08-19
US20040096901A1 (en) 2004-05-20
JP2004533816A (ja) 2004-11-11
EP1421191A2 (de) 2004-05-26
CZ20032129A3 (cs) 2003-11-12
RU2328506C2 (ru) 2008-07-10
JP2009034108A (ja) 2009-02-19
IL157136A0 (en) 2004-02-08
ZA200305911B (en) 2004-06-28
PE20020871A1 (es) 2002-11-11
ATE526409T1 (de) 2011-10-15
WO2002072832A2 (en) 2002-09-19
HK1071769A1 (zh) 2005-07-29
KR20040036684A (ko) 2004-04-30
PL369516A1 (en) 2005-04-18
CA2437963A1 (en) 2002-09-19
NZ548865A (en) 2008-03-28
HUP0401560A3 (en) 2012-09-28
RU2003126168A (ru) 2005-03-10
ECSP034714A (es) 2003-09-24
MXPA03007197A (es) 2003-12-04
BR0207151A (pt) 2004-10-05
NO20033549D0 (no) 2003-08-11
HUP0401560A2 (hu) 2004-11-29
TWI332524B (en) 2010-11-01
NO20033549L (no) 2003-10-10

Similar Documents

Publication Publication Date Title
US7825222B2 (en) Therapeutic binding molecules
KR100752029B1 (ko) 치료용 결합 분자
KR20100035643A (ko) 성숙 수지상 세포에서의 허용유발 표현형의 유도
AU2004272289B2 (en) Therapeutic binding molecules
KR102951376B1 (ko) Dll3에 대한 키메라 수용체 및 이의 사용 방법
CN109414455B (zh) Bcma结合分子及其使用方法
US20090246204A1 (en) Use of a cd28 binding substance for making a pharmaceutical composition
TW202305113A (zh) 用於自經誘導之多能幹細胞產生γδ T細胞的組合物及方法
KR101831229B1 (ko) Ｈｓｐ65-유도 펩티드-6에 특이한 인간화 항체, 그것의 방법 및 용도
AU2006203778B2 (en) Therapeutic binding molecules
AU2002231795A1 (en) Therapeutic binding molecules
HK1071769B (en) Therapeutic binding molecules
MXPA06003128A (en) Therapeutic binding molecules
AU2022230717A1 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
HK40000650B (en) Bcma binding molecules and methods of use thereof
AU2014200678A1 (en) Antibodies to CD200 and uses thereof in inhibiting immune responses

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure